FemRx' Opera Star cleared for US marketing
This article was originally published in Clinica
Gynaecology specialist FemRx has received 510(k) clearance for its minimally invasive alternative to hysterectomy, the Opera Star system. The Out-Patient Endometrial Resection/Ablation device treats abnormal uterine bleeding in most patients without the need for an incision (see Clinica No 696, p 10). The system consists of a Specialised Tissue Aspirating Resectoscope which enables gynaecological surgeons to resect and ablate the endometrial lining and remove fibroids while continuously aspirating tissue for pathological evaluation.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.